OneSource Specialty Pharma and Formycon AG announce Strategic Manufacturing Partnership for Biosimilars

OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE), a multi-modality specialty pharma CDMO, and Formycon AG (FSE: FYB, Prime Standard, "Formycon"), an independent biosimilar developer headquartered in Munich, today announced a strategic manufacturing partnership for biosimilars.

Under the partnership, OneSource will serve as a strategic manufacturing partner for Formycon and provide integrated Drug Substance (DS) and Drug Product (DP) manufacturing capabilities from its state-of-the-art biologics' facility in Bangalore. The collaboration brings together Formycon´s Biosimilar development excellence with OneSource's end-to-end biologics manufacturing expertise to support Formycon's biosimilar programs for global markets.

The partnership reflects the shared commitment of both companies to advancing global access to biosimilars through reliable, high-quality, and scalable manufacturing. Achieving this requires not only scientific excellence but also a sustainable, cost-effective manufacturing model - that OneSource is specifically positioned to deliver.

Formycon brings a strong track record in biosimilar development and commercialization, supported by an established portfolio and a robust pipeline. OneSource complements this with an integrated biologics platform spanning cell line development through commercial fill-finish, five manufacturing facilities approved by leading global regulatory authorities, including the US FDA and EMA, and extensive expertise across biologics, sterile injectables, and drug-device combinations.

Neeraj Sharma, Managing Director & CEO, OneSource Specialty Pharma, said: "We are delighted to partner with Formycon, one of the world's leading biosimilar developers with a proven track record of bringing high-quality biosimilars to global markets. This partnership brings together Formycon's development expertise and OneSource's integrated manufacturing capabilities to expand access to high-quality, affordable biologics for patients worldwide. It also reinforces our belief that India is uniquely positioned to serve as a global hub for the development and manufacture of world-class biologics."

Dr. Stefan Glombitza, Chief Executive Officer of Formycon AG, said: "Reliable, scalable and cost-efficient manufacturing is a cornerstone of our FYB4Growth strategy. By adding OneSource to our network of strategic manufacturing partners, we are further strengthening our supply capabilities with a partner that meets our unwavering commitment to high standards of quality, operational excellence and cost-efficiency. Together, we aim to broaden sustainable global access to life-changing biosimilar therapies."

Shares of Onesource Specialty Pharma Limited was last trading in BSE at Rs. 1649.10 as compared to the previous close of Rs. 1671.65. The total number of shares traded during the day was 36948 in over 762 trades.

The stock hit an intraday high of Rs. 1704.85 and intraday low of 1616.75. The net turnover during the day was Rs. 60421987.00.

Source : Equity Bulls

Keywords

OnesourceSpecialtyPharma INE013P01021 FormyconAG Biosimilar Partnership